Ulixacaltamide

Ulixacaltamide
Clinical data
Other names	PRAX-944, Z 944
Identifiers
	IUPAC name N-[[1-[2-(tert-butylamino)-2-oxoethyl]piperidin-4-yl]methyl]-3-chloro-5-fluorobenzamide;
CAS Number	1199236-64-0;
PubChem CID	44540045;
DrugBank	DB18788;
ChemSpider	29788896;
UNII	QT2PJH89C3;
KEGG	D12819;
ChEBI	CHEBI:194339;
ChEMBL	ChEMBL3934636;
Chemical and physical data
Formula	C19H27ClFN3O2
Molar mass	383.89 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C)NC(=O)CN1CCC(CC1)CNC(=O)C2=CC(=CC(=C2)Cl)F;
	InChI InChI=InChI=1S/C19H27ClFN3O2/c1-19(2,3)23-17(25)12-24-6-4-13(5-7-24)11-22-18(26)14-8-15(20)10-16(21)9-14/h8-10,13H,4-7,11-12H2,1-3H3,(H,22,26)(H,23,25); Key:JOCLITFYIMJMNK-UHFFFAOYSA-N;

Ulixacaltamide is an investigational new drug developed by Praxis Precision Medicines, designed to treat essential tremor,^[1] a common neurological disorder characterized by involuntary rhythmic shaking. It functions as a selective inhibitor of T-type calcium channels, which are implicated in the abnormal neuronal activity associated with tremor.^[2] The drug is currently undergoing Phase 3 clinical trials.^[3]

References

^ "Ulixacaltamide - Praxis Precision Medicine". AdisInsight. Springer Nature Switzerland AG.
^ Scott L, Puryear CB, Belfort GM, Raines S, Hughes ZA, Matthews LG, et al. (June 2022). "Translational Pharmacology of PRAX-944, a Novel T-Type Calcium Channel Blocker in Development for the Treatment of Essential Tremor". Movement Disorders : Official Journal of the Movement Disorder Society. 37 (6): 1193–1201. doi:10.1002/mds.28969. PMC 9310641. PMID 35257414.
^ Clinical trial number NCT06087276 for "Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)" at ClinicalTrials.gov

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] "Ulixacaltamide - Praxis Precision Medicine". AdisInsight. Springer Nature Switzerland AG.

[pmid35257414-2] Scott L, Puryear CB, Belfort GM, Raines S, Hughes ZA, Matthews LG, et al. (June 2022). "Translational Pharmacology of PRAX-944, a Novel T-Type Calcium Channel Blocker in Development for the Treatment of Essential Tremor". Movement Disorders : Official Journal of the Movement Disorder Society. 37 (6): 1193–1201. doi:10.1002/mds.28969. PMC 9310641. PMID 35257414.

[3] Clinical trial number NCT06087276 for "Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)" at ClinicalTrials.gov

[1]

[2]

[3]